Literature DB >> 8217799

Expression of GpIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease.

M L Scrobohaci1, M T Daniel, Y Levy, J P Marolleau, J C Brouet.   

Abstract

To get insights into the pathogenesis of acquired von Willebrand disease associated with plasma cell dyscrasias, we searched for the expression of the physiological von Willebrand factor receptor, the GpIb/GpIX complex, on bone marrow plasma cells. The monoclonal spike in our patient corresponded to IgG kappa molecules; there was no plasma inhibitor to vWF:Ag or vWF:RiCoF. The bone marrow contained 1-2% plasma cells. Fresh bone marrow cells or plasma cells enriched bone marrow cells after a 48 h in vitro culture in the presence of interleukin 6 were stained by an immuno alkaline phosphatase technique using monoclonal antibodies (mAb) to von Willebrand factor, GpIb alpha and beta chain, GpIIb/IIIa and Gp IX. Two different mAb to GpIb alpha chains reacted with the majority (75%) of plasma cells whereas all other reagents yielded no staining. Malignant plasma cells from patients with multiple myeloma without haemostatic disorder were unreactive with anti-GpIb mAb. These data suggest that in some patients with acquired von Willebrand syndrome there is a GpIb mediated selective adsorption of von Willebrand factor on clonal plasma cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8217799     DOI: 10.1111/j.1365-2141.1993.tb03103.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

Review 1.  Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.

Authors:  Hiroshi Mohri
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

Review 2.  Acquired von Willebrand syndrome: focused for hematologists.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2020-06-18       Impact factor: 9.941

Review 3.  The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies.

Authors:  Claire Comerford; Siobhan Glavey; John Quinn; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2022-06-23       Impact factor: 16.036

4.  Multiple Myeloma as the Underlying Cause of Thrombotic Microangiopathy Leading to Acute Kidney Injury: Revisiting a Very Rare Entity.

Authors:  Savneek Chugh; Asim Kichloo; Firas Jafri; Liga Yusvirazi; Robert Lerner
Journal:  J Investig Med High Impact Case Rep       Date:  2017-09-22

Review 5.  The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer.

Authors:  Chanukya K Colonne; Emmanuel J Favaloro; Leonardo Pasalic
Journal:  Healthcare (Basel)       Date:  2022-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.